// App-Quantinova.ai

TPS4139 : Pembrolizumab for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: phase 2 KEYNOTE-180 study.

Researchers

Presenter

  • Manish A. Shah

Principal Investigators

  • Jaafar Bennouna

  • Lin Shen

  • Peter C. Enzinger

  • Qiao Li

  • Ildiko Csiki

  • Minori Koshiji

  • Toshihiko Doi

Medical Centers

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Dana-Farber Cancer Institute, Boston, MA

  • MSD China, Beijing, China

  • Merck & Co., Inc., Kenilworth, NJ

  • Merck & Co. Inc., Rahway, NJ

  • National Cancer Center Hospital, Tokyo, Japan

Locations

  • United States

  • China

  • France

  • Japan

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Squamous cell carcinoma

  • Brain metastasis

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Pembrolizumab

  • Trastuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02559687

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved